The Translational Genomics Research Institute has appointed Elizabeth Montemayor as CFO, and Ron King as director of technology transfer.
Montemayor comes to TGen from the Cancer Therapy and Research Center in San Antonio, Texas, where she was the CFO. King, meantime, was the founding director of the technology transfer office at the National Human Genome Research Institute at the National Institutes of Health.
DNAPrint Genomics has rounded out its senior executive staff by hiring Hector Gomez as chief medical officer. The appointment comes less than three weeks after the company hired Monica Tamborini to be chief financial and operations officer.
Gomez has been DNAPrint board member, and later its chairman, since 2002, and was most recently president and CEO of Transcend Therapeutics until 1998.
Perlegen Sciences has appointed Mark McCamish to the newly created role of chief medical officer and vice president of clinical development.
“Perlegen is moving rapidly toward the in-licensing of late-stage drug candidates that have been blocked in development after the pharmaceutical companies developing them have observed possible genetic differences in patients’ response,” Brad Margus, Perlegen’s CEO, said in a statement.
McCamish comes to Perlegen from Amgen, where he led the company’s efforts to develop and commercialize drugs in cardiac, pulmonary, and other chronic disease indications. Previously, he was clinical studies management team leader at Amgen, where he was responsible for worldwide clinical research, which focused on leptin receptor-directed therapeutics for the treatment of obesity, diabetes, and leptin deficiency.
McCamish has held faculty positions at the University of California at Davis, Michigan State University, and Ohio State University. He holds an MD from the University of California, Los Angeles School of Medicine, and a PhD from Pennsylvania State University.